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expression vector for mammalian cells
Rudolf Haase†1,4, Orestis Argyros†2, Suet-Ping Wong2, Richard P Harbottle2, Hans J Lipps3, Manfred Ogris4, 
Terese Magnusson4, Maria G Vizoso Pinto1, Jürgen Haas1,5 and Armin Baiker*1
Abstract
Background: The episomal replication of the prototype vector pEPI-1 depends on a transcription unit starting from 
the constitutively expressed Cytomegalovirus immediate early promoter (CMV-IEP) and directed into a 2000 bp long 
matrix attachment region sequence (MARS) derived from the human β-interferon gene. The original pEPI-1 vector 
contains two mammalian transcription units and a total of 305 CpG islands, which are located predominantly within 
the vector elements necessary for bacterial propagation and known to be counterproductive for persistent long-term 
transgene expression.
Results: Here, we report the development of a novel vector pEPito, which is derived from the pEPI-1 plasmid replicon 
but has considerably improved efficacy both in vitro and in vivo. The pEPito vector is significantly reduced in size, 
contains only one transcription unit and 60% less CpG motives in comparison to pEPI-1. It exhibits major advantages 
compared to the original pEPI-1 plasmid, including higher transgene expression levels and increased colony-forming 
efficiencies in vitro, as well as more persistent transgene expression profiles in vivo. The performance of pEPito-based 
vectors was further improved by replacing the CMV-IEP with the human CMV enhancer/human elongation factor 1 alpha 
promoter (hCMV/EF1P) element that is known to be less affected by epigenetic silencing events.
Conclusions: The novel vector pEPito can be considered suitable as an improved vector for biotechnological 
applications in vitro and for non-viral gene delivery in vivo.
Background
The non-viral plasmid vector pEPI-1 was constructed in
1999 by Piechaczek et al [1], by cloning a 2000 bp long
matrix attachment region sequence (MARS), that was
derived of the human β-interferon gene cluster [2], into
the commercial vector pGFP-C1 (Clontech, USA). The
pEPI-1 vector contains a total of 305 CpG motives, most
of them within the vector elements necessary for bacte-
rial propagation. Furthermore, pEPI-1 consists of two
mammalian transcription units oriented in a clockwise
direction. The first, Cytomegalovirus immediate early
promoter (CMV-IEP) driven enhanced green fluorescent
protein (EGFP) transcription unit is oriented into the
MARS and has been shown to be a functional component
of the pEPI-1 vector plasmid replicon. The second, Sim-
ian Virus 40 Ori/promoter (SV40-O/P) driven neomycin
phosphotransferase (NPT) transcription unit has been
used for bacterial and mammalian selection purposes,
but is dispensable for the vectors' episomal replication in
mammalian cells. pEPI-1 replicates episomally in a copy
number of approximately 5-10 molecules per cell in all
mammalian cell lines tested, is mitotically stable even in
the absence of selection and facilitates long-term expres-
sion of transgenes or shRNA's [1,3-5]. The vector repli-
cates once per cell cycle during early S-phase, with the
origin recognition complex (ORC) being able to assemble
at various regions on the vector DNA [6]. The episomal
replication is due to stable association with early replica-
tion foci by MARS mediated binding to the nuclear
matrix protein scaffold attachment factor A (SAF-A).
Within early replication foci, DNA replication of pEPI-1
vector molecules is likely facilitated by a conformational
change resulting from mRNA transcription [3,7,8] (Fig-
ure 1A). The mitotic stability of pEPI-based vectors can
be explained by the MARS mediated stable interaction
with metaphase chromosomes [3] (Figure 1B). The func-
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Page 2 of 14tional element of the pEPI-1 plasmid replicon could be
mapped as transcription unit, regulated by a constitutive
promoter and directed into a chromosomal MARS with-
out termination signal between transcription unit and
MARS [9] (Figure 1C).
Similar to EBV plasmid replicons administered as
naked DNA, the establishment of stable pEPI-1 episomes
in transfected cells is very inefficient [1,10]: only 0.5-5%
of transiently pEPI-1-transfected cells develop stable
clones. This is also the case when pEPI-1 plasmids are
isolated from already established mammalian cell clones
and reintroduced into cells demonstrating that the pri-
mary sequence of DNA is not involved in the establish-
ment process [8,11,12] but rather epigenetic features such
as chromatin structure and nuclear localization [8].
A cytosine monophosphate (C) followed by a guanine
monophosphate (G) in a nucleotide sequence is referred
to as CpG dinucleotide (or CpG islands). In eukaryotic
DNA, CpG dinucleotides in eukaryotes appear at lower
frequency and are often methylated to 5-methyl-cytosine
(mCpG), whereas in most bacterial genomes, however,
CpG dinucleotides are represented according to their sta-
tistical expectation, and the cytosine residue is normally
unmethylated [13,14]. The human innate immune system
has evolved mechanisms to differentiate bacterial DNA
from its own via Toll-like receptor 9 (TLR 9) signalling.
TLR9 interacts with endocytosed DNA comprising unm-
ethylated CpG dinucleotides and triggers downstream
signalling via MyD88, IRAK and TRAF6 to increase NFêB
and AP1 expression. This in turn results in the produc-
tion of inflammatory cytokines [15,16]. In fact, Hyde et al.
demonstrated that a single CpG motif present in a DNA
vector backbone elicits an inflammation after pulmonary
delivery in vivo [17].
The majority of human promoters belong to the high-
CpG class of promoters, for which it is well established
that the methylation status of the surrounding CpG
islands has a direct influence on the promoter activity
unmethylated CpG islands in the promoter region corre-
spond to active promoters, whereas heavily methylated
mCpG islands correspond to inactive promoters [18]. The
CMV-IEP is most often used in commercial vectors con-
ferring robust expression of a transgene in several cell
types. This strong activity is due to the presence of sev-
eral transcription factor binding sites within its sequence.
The expression profile of CMV-IEP typically peaks at
around 1-2 days after vector administration, followed by a
steady decrease in its activity over a period of 1-2 weeks.
Methylation of CpG islands within the CMV-IEP region
has been suggested as one explanation for this long-
known, but undesired silencing phenomenon [19], even if
recent publications indicate other mechanisms for this
effect [20,21].
Taken together, these findings suggest that a state of the
art plasmid vector for gene delivery into mammalian cells
should be composed of a promoter element that is
depleted of CpG islands in order to minimize silencing
phenomena, and a CpG depleted vector backbone to pre-
vent undesired stimulatory effects on the innate immune
system [16,22]. Such optimized plasmid vectors have
already been realized as CpG depleted vectors [17,23]
Figure 1 Mechanism of persistence of MARS-containing pEPI-1 
vectors. (A) Episomal replication can be explained by a stable associa-
tion with early replication foci mediated by the MARS mediated bind-
ing to the nuclear matrix protein scaffold attachment factor A (SAF-A). 
Within early replication foci, the assembly of the origin recognition 
complex (ORC) and the DNA replication of pEPI vector molecules is 
likely facilitated by a conformational change resulting from mRNA 
transcription.(B) Nuclear retention and mitotic stability of pEPI-based 
vectors can be explained by MARS mediated direct or indirect interac-
tion with metaphase chromosomes in a "piggy back"-like mechanism. 
(C) The functional element of pEPI-vector plasmid replicons consists of 
a transcription unit, regulated by a constitutive promoter and directed 
into a chromosomal MARS with the prerequisite of no termination sig-
nal being located between transcription unit and MARS element.
Haase et al. BMC Biotechnology 2010, 10:20
http://www.biomedcentral.com/1472-6750/10/20
Page 3 of 14exhibiting increased levels and persistence of transgene
expression, as well as reduced inflammation in vivo.
In the present study we hypothesized that pEPI-1 based
plasmid replicons can be improved by reducing the CpG
content in the vector backbone to achieve more efficient
transgene expression in vitro and in vivo. The novel vec-
tor named pEPito has been constructed by cloning the
pEPI-1 plasmid replicon into a plasmid backbone without
CpG islands and omitting a second transcription unit.
Herein we demonstrate that the novel pEPito vector
exhibits several advantages over its precursor pEPI-1,
including higher transgene expression levels and colony-
forming efficiencies in vitro and more persistent trans-
gene expression profiles in vivo. Additionally, the perfor-
mance of all vectors is improved when replacing the
CMV-IEP by the human CMV enhancer/human elonga-
tion factor 1 alpha promoter (hCMV/EF1P) element, that
is known to be less affected by epigenetic silencing events
[17].
Results
Generation of pEPI-based vectors with improved efficacy
We systematically generated a panel of 13 different pEPI-
1-derived vectors, all of them constructed in a modular
way enabling the easy exchange of backbone, promoter,
or transgene elements by restriction digest with PciI,
NheI, BglII, or MluI (Figure 2). Vectors based on the
pEPI-1 backbones contain a pUC Ori for bacterial propa-
gation, a MARS, a second mammalian SV40-O/P driven
NPT transcription unit for bacterial kanamycin or mam-
malian geneticin (G418) selection purposes, and a total of
206 CpG motives. The pEPito backbones contain a R6K
Ori [24] for bacterial propagation, a β-lactamase gene
(BLA) for bacterial ampicillin selection, a MARS, no sec-
ond mammalian transcription unit, and only 37 CpG
motives. Control vectors pEPI-1-ΔMARS and pEPito-
ΔMARS without MARS elements contain a total of 207
and 38 CpG motives, respectively. All vectors contain
either the CMV-IEP, or the hCMV/EF1P promoter ele-
ment, with the latter one known to be less affected by epi-
genetic silencing events [17]. Depending on the
experiment, three different transgenes have been used: an
EGFP-BSD cassette with which both eGFP (enhanced
green fluorescent protein) and BSD (Blasticidine S deami-
nase) are expressed via a synthetic internal ribosomal
entry site (EGFP-IRES-BSD) [25], a Firefly luciferase (Luc)
[26,27], or an EGFP-luciferase fusion protein (EGFP::Luc)
[27-29]. All 13 different vectors have been constructed,
propagated, and amplified in E.coli DB3.1ëpir [30].
Increased transgene expression and colony formation of 
pEPito vectors in vitro
In order to compare the novel CpG depleted pEPito vec-
tor backbone with the original pEPI-1 vector backbone, a
set of eight novel vectors were constructed (Figure 2E, #1-
8). All novel vectors comprised an identical transgene, i.e.
an EGFP-BSD cassette connected via a recently
described, 22 bp long internal ribosomal entry site
(EGFP-IRES-BSD) [25]. This cassette enabled both the
analysis of transgene (EGFP) expression by flow cytome-
try and the selection of transfected mammalian cells with
blasticidin.
In vitro experiments were performed in HEK293 and
NIH3T3 cells, with the latter cell line having shown to
silence exogenous DNA rapidly [31] (Figure 3). Equal
amounts of vector DNA were used to exclude undesired
effects of any added stuffer DNA, as for example soni-
cated salmon sperm DNA or any other small plasmid
DNA with varying CpG contents. Transient transfection
results assayed by flow cytometry of EGFP positive cells
48 hours post transfection are shown (for representative
FACS diagrams see additional file 1). On HEK293 cells,
all pEPito-based vectors exhibited transfection efficien-
cies of around 75%, independent of plasmid size, pro-
moter type, or the presence or absence of the MARS
element, whereas with all pEPI-1 based vectors 45-65%
EGFP positive cells were found (Figure 3A). pEPI-1 based
vectors with hCMV/EF1P promoter element resulted in
the lowest transient transfection efficiencies, indicating
an effect of the used promoter elements. When perform-
ing identical experiments on NIH3T3 cells, overall lower
transient transfection efficiencies were observed, ranging
from 4% to 16% (Figure 3B). The pEPito-ΔMARS vectors,
the smallest vectors used, exhibited the highest transient
transfection efficiency indicating either an inverted effect
of the plasmid size, or an effect of the initial molar
amount of DNA used for transfection or both. In pEPI-1
based vector constructs the hCMV/EF1P promoter ele-
ment exhibit lower transient transfection efficiencies
compared to the CMV-IEP promoter element, and
smaller, MARS depleted vectors exhibit higher transfec-
tion efficiencies compared to the larger plasmid con-
structs.
When analyzing the level of EGFP per cell, the mean
EGFP intensity levels HEK293 cells were not significantly
different in six out of the eight novel vector constructs
(Figure 3C). Only pEPI-1- [hCMV/EF1P]- [EGFP-IRES-
BSD] and pEPI-1- [hCMV/EF1P]- [EGFP-IRES-BSD]-
ΔMARS resulted in a lower EGFP signal indicating an
effect of the promoter elements only within the pEPI-1
vector backbone (Figure 3C). In NIH3T3 cells, pEPito
based vectors with hCMV/EF1P promoter resulted in
slightly higher EGFP expression levels as compared to the
CMV-IEP (Figure 3D). In contrast, pEPI-based vectors
with CMV-IEP promoter always resulted in slightly
higher expression levels as the respective hCMV/EF1P
promoter constructs. In concordance with transfection
efficiencies, the overall mean intensity of the EGFP signal,
Haase et al. BMC Biotechnology 2010, 10:20
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Page 4 of 14however, was much weaker in NIH3T3 cells than in
HEK293.
For further analysis, stably selected mixed-clone cells
were generated from initially transfected cells as batch by
selection with blasticidin for 30 days. When selecting
HEK293 cells transfected with the eight different vector
constructs, stably selected mixed-clone cells could be
obtained in all cases (Figure 4A, C). In HEK293 cells the
mean EGFP signal intensity per cell was influenced by the
promoter element used, the nature of the vector back-
bone, and the presence or absence of a MARS. Vectors
with the CMV-IEP promoter element exhibited higher
EGFP expression levels as compared to their correspond-
ing vectors with the hCMV/EF1P promoter element. Fur-
thermore, pEPito-based vectors always exhibited higher
expression levels compared to their respective pEPI-1-
based counterparts. Finally, vectors with a MARS ele-
ment always performed better than their MARS depleted
controls, with respect to the EGFP expression level (Fig-
ure 4A, for representative FACS diagrams see additional
file 2). With NIH3T3 cells, stably selected mixed-clone
cells could not be obtained with the three CMV-IEP pro-
moter element containing constructs indicating a nega-
tive effect of the CMV-IEP promoter element on the
establishment of stable NIH3T3 cell lines (Figure 4B, D).
The mean EGFP signal intensity per cell was mainly influ-
enced by the promoter element and the nature of the vec-
tor backbone used, as the CpG depleted pEPito vectors
always performed better than their pEPI-1-based coun-
terparts. As most vectors based on the CMV-IEP pro-
moter element could not be selected to obtain stable
mixed-clones and that the vector pEPito- [CMV-IEP]-
[EGFP-IRES-BSD] exhibits a weaker mean EGFP signal
intensity then the vector pEPito- [hCMV/EF1P]- [EGFP-
Figure 2 pEPI-derived plasmids generated in this study. A schematic picture of the four types of vector backbones is depicted in the upper panel: 
pEPI-1 (A), pEPito (B), pEPI-1-ΔMARS (C), or pEPito-ΔMARS (D). All vectors contain either the CMV-IEP or the hCMV/EF1P promoter element. Depending 
on the experiment, three different transgenes have been used: an EGFP-BSD cassette connected via an internal ribosomal entry site module (EGFP-IRES-
BSD), a Firefly luciferase (Luc), or an EGFP-luciferase fusion protein (EGFP::Luc). All 13 different vectors have been constructed, propagated, and amplified 
in E.coli DB3.1λpir. (E) Additional information regarding the different vectors. The vector pEPI-1- [CMV-IEP]- [Luc] has been recently published as pEPI-
Luc [32]. This figure does not claim proportional correctness.
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Page 5 of 14IRES-BSD], we conclude that the promoter element has a
strong influence on the EGFP expression levels in
NIH3T3 cells. In contrast to HEK293 cells, the promoter
preference is inverted in NIH3T3 cells with the hCMV/
EF1P always performing better than the CMV-IEP pro-
moter element (Figure 4B).
The episomal status of all four MARS bearing vectors
could be verified by bacterial rescue experiments using
chromosomal DNA extracted from stably selected
HEK293 mixed-clones. Rescued plasmids did not exhibit
any rearrangements as checked by restriction analysis
and gel electrophoresis (data not shown). The plasmids
pEPito- [hCMV/EF1P]- [EGFP-IRES-BSD] and pEPito-
[CMV-IEP]- [EGFP-IRES-BSD] could be rescued from
chromosomal DNA extracted from stably selected
NIH3T3 cells, but no MARS depleted control vector
could be rescued (Table 1).
To further analyze colony-forming efficiencies of the
eight novel vectors, transfected HEK293 and NIH3T3
cells were serially diluted and selected with blasticidin. In
case of HEK293 cells the results of the colony-forming
assays performed are presented as fold increase in rela-
Figure 3 Transfection efficiencies and expression levels in transiently transfected HEK293 and NIH3T3 cells. Transient transfection efficiencies 
(A, B) and the transient mean EGFP expression levels per cell (C, D) obtained by transfection of the vectors #1-8 into HEK293 cells (A, C), or NIH3T3 
cells (B, D). All vectors contain the EGFP-IRES-BSD transgene transcription unit. Mean values of n = 8 derived from four independent experiments ± 
SD are shown; * p < 0.05; ** p < 0.001 (two-tailed Student's t-test). mock: untransfected control. Grey bars indicate vectors containing an hCMV/EF1P 
promoter element, black bars indicate vectors containing a CMV-IEP promoter element.
Haase et al. BMC Biotechnology 2010, 10:20
http://www.biomedcentral.com/1472-6750/10/20
Page 6 of 14tion to pEPI-1- [CMV-IEP]- [EGFP-IRES-BSD]-ΔMARS
(Figure 4C). Since this vector did not result in any stably
selected NIH3T3 cells, the results of the colony-forming
assays in NIH3T3 cells are presented as fold increase in
relation to pEPI-1- [hCMV/EF1P]- [EGFP-IRES-BSD]-
ΔMARS, (Figure 4D). In HEK293 cells, pEPito- [CMV-
IEP]- [EGFP-IRES-BSD] exhibited a ~70 fold increased
colony-forming efficiency over its pEPI-ΔMARS-control,
followed by a ~45 fold increase within pEPito- [hCMV/
EF1P]- [EGFP-IRES-BSD], indicating a positive effect of
the MARS sequence in the pEPito vector backbone on
colony-forming efficiency. Vectors based on the pEPito-
ΔMARS or pEPI-1 vector backbones exhibited a ~10 fold
increased colony-forming efficiency as compared to the
Figure 4 Expression levels and colony formation efficiencies in stably selected HEK293 and NIH3T3 cells. (A, B) Mean EGFP expression levels 
per cell (A: HEK293, B: NIH3T3) of stably selected cells. (C, D) Relative colony-forming efficiency of stably selected HEK293 cells (C, normalized to pEPI-
1- [CMV-IEP]- [EGFP-IRES-BSD]-ΔMARS) or NIH3T3 cells (B, normalized to pEPI-1- [hCMV/EF1P]- [EGFP-IRES-BSD]-ΔMARS. All vectors contain the EGFP-
IRES-BSD transgene transcription unit. Mean values of n = 8 derived from four independent experiments ± SD are shown; * p < 0.05; ** p < 0.001 (two-
tailed Student's t-test). mock: untransfected control. n.d.: no stable mixed-clones obtained after transfection and blasticidin selection. Grey bars: vec-
tors containing the hCMV/EF1 promoter element; black bars: vectors containing the CMV-IEP promoter element.
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le 1: Rescue of plasmids from stably transfected cells and injected mice
v
Tab# plasmid HEK293
30 d.p.t.
NIH3T3
30 d.p.t.
mouse liver
32 d.p.i.
1 pEPI-1- [CMV-IEP]- 
[EGFP-IRES-BSD]
3/3 0/9 n.a.
2 pEPI-1- [CMV-IEP]- 
[EGFP-IRES-BSD]-
MARS
0/9 0/9 n.a.
3 pEPI-1- [hCMV/EF1P]- 
[EGFP-IRES-BSD]
3/3 -/9 n.a.
4 pEPI-1- [hCMV/EF1P]- 
[EGFP-IRES-BSD]-
MARS
-/9 -/9 n.a.
5 pEPito- [CMV-IEP]- 
[EGFP-IRES-BSD]
3/3 3/3 n.a.
6 pEPito- [CMV-IEP]- 
[EGFP-IRES-BSD]-
MARS
-/9 0/9 n.a.
7 pEPito- [hCMV/EF1P]- 
[EGFP-IRES-BSD]
3/3 3/3 n.a.
8 pEPito- [hCMV/EF1P]- 
[EGFP-IRES-BSD]-
MARS
-/9 -/9 n.a.
9 pEPI-1- [CMV-IEP]- 
[Luc]
n.a. n.a. -/9
10 pEPito- [CMV-IEP]- 
[EGFP::Luc]
n.a. n.a. 3/3
11 pEPito- [CMV-IEP]- 
[EGFP::Luc]- MARS
n.a. n.a. -/9
12 pEPito- [hCMV/EF1P]- 
[EGFP::Luc]
n.a. n.a. 3/3
13 pEPito- [hCMV/EF1P]- 
[EGFP::Luc]- MARS
n.a. n.a. -/9
First column: consecutive vector numbers and systematic vector names. Second and third column: rescue from HEK293 and NIH3T3 at 30 
days post transfection (d.p.t.). Fourth column: rescue from mouse genomic liver DNA of mice sacrificed at 32 days post injection (d.p.i.). The 
first number always indicates the number of rescue experiments were plasmid DNA could be rescued without any rearrangement from the 
isolated chromosomal DNA. The second number indicates the total number of performed rescue experiments. '-' indicates that no clones 
could be obtained by a particular rescue experiment; n.a.: not assayed.
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HEK293 cells, indicating a positive effect of the CpG
depleted pEPito-ΔMARS vector backbone or the pres-
ence of a MARS element on colony-forming efficiency
(Figure 4C).
In NIH3T3 cells, only vectors based on the hCMV/EF1
promoter element resulted in significant numbers of
formed colonies (Figure 4D): pEPito- [hCMV/EF1P]-
[EGFP-IRES-BSD] exhibited a ~100 fold increased col-
ony-forming efficiency as compared to pEPI-1- [hCMV/
EF1P]- [EGFP-IRES-BSD]-ΔMARS indicating a positive
effect of the pEPito vector backbone. Vectors based on
the pEPito-ΔMARS vector backbones exhibited a ~10
fold increased colony-forming efficiency as compared to
the vectors based on the pEPI-1-ΔMARS vector back-
bones indicating a positive effect of the CpG depleted
pEPito-ΔMARS vector backbone on colony establish-
ment.
Increased expression and stability of pEPito vectors in 
murine liver in vivo
The in vivo performance of the novel pEPito vector back-
bones was studied in MF-1 mice by hydrodynamic injec-
tion of 30 μg of respective vectors intravenously into MF-
1 mice and the transgene expression in the liver measured
over time by bioluminescence imaging as described ear-
lier [32]. For this purpose, a set of four novel pEPito vec-
tors were constructed containing the EGFP::Luc fusion
protein as transgene transcription unit. (Figure 2E, #10-
13). The vector pEPI-1- [CMV-IEP]- [Luc] (#9) has been
included as additional control (recently published as
pEPI-Luc [32]), which contains a Firefly luciferase (Luc)
transgene instead of the EGFP::Luc fusion protein (Figure
2E, #9). The sequences of both luciferases, however, are
identical. In concordance with all previous (in vitro)
experiments, equal amounts of vector DNA have been
injected, in order to avoid undesired effects of any added
stuffer DNA. Luciferase activity was quantified after 1, 7,
14, 21 (data not shown) and 32 days post injection (d.p.i.)
(Figure 5, for quantifications see additional file 3). All ani-
mals exhibited an equally strong luciferase signal on day
one after injection, at later time points the luciferase sig-
nal steadily decreased. With the pEPI-1 based control
vector pEPI-1- [CMV-IEP]- [Luc], and in the two MARS
depleted pEPito control vectors pEPito- [CMV-IEP]-
[EGFP::Luc]-ΔMARS and pEPito- [hCMV/EF1P]-
[EGFP::Luc]-ΔMARS the luciferase signal is weakly
detectable until 14 d.p.i., but is below detection limit at 32
d.p.i This result indicated a positive effect of the pEPito
vector backbone and the MARS element on prolonged
luciferase expression. In contrast, the two pEPito based
vectors pEPito- [CMV-IEP]- [EGFP::Luc] and pEPito-
[hCMV/EF1P]- [EGFP::Luc] exhibit a longer lasting
luciferase expression until 32 d.p.i Obviously, the pEPito
vector with the hCMV/EF1P promoter element exhibited
the strongest in vivo luciferase expression 32 d.p.i., about
5 fold higher compared to the CMV-IEP in pEPito and
more than a 2 log difference to pEPI-Luc indicating a pos-
itive effect of the hCMV/EF1P promoter element on pro-
longed transgene expression in MF-1 mice in vivo. After
sacrificing all animals at 32 d.p.i., chromosomal DNA was
extracted from their livers. In order to estimate the copy
numbers of vector molecules present in liver tissues a
quantitative PCR (qPCR) was performed. Vector DNA
could be detected in all animals at 32 d.p.i The copy num-
ber of vector molecules as detected by qPCR varied
between 0.5 - 6 vector molecules per liver cell, but did not
vary significantly within the livers of the animals injected
with any of the five different vector constructs, implying
that no degradation (loss) of vector DNA is responsible
for the decrease in the luciferase signal over time (data
not shown). As indicated in Table 1, the two pEPito based
vectors with MARS element, i.e. pEPito- [CMV-IEP]-
[EGFP::Luc] and pEPito- [hCMV/EF1P]- [EGFP::Luc],
could be rescued from chromosomal liver DNA prepara-
tions without any rearrangements at 32 d.p.i., indicating
that the presence of a MARS element within the pEPito
vector backbone facilitates the persistence of episomes in
a "rescue"-able form in vivo. We did not succeed in rescu-
ing pEPI- [CMV-IEP]-Luc.
Discussion
In this manuscript we present a novel pEPI-vector deriva-
tive, named pEPito, with higher transgene expression lev-
els and increased colony-forming efficiencies in vitro, and
more persistent transgene expression profiles in vivo. In
order to compare the novel pEPito-backbone with the
backbone of the original vector, pEPI-1, a series of 13
novel vectors was constructed. Eight vectors, comprising
an identical transgene transcription unit, i.e. EGFP-IRES-
BSD, were generated to evaluate vector-backbone perfor-
mance in vitro. These eight vector constructs were subse-
quently selected for BSD expression, present in the first
transgene transcription unit that is part of the pEPI-vec-
tors' episomal plasmid replicon (Figure 1). This is note-
worthy, since all previous pEPI-1 based vectors were
selected for the NPT gene, present in the second dispens-
able SV40-O/P driven transcription unit [1,3,4]. It is also
worth mentioning, that in previous studies the expression
of the first, CMV-IEP promoter driven transgene tran-
scription unit has not been studied extensively, since
main focus was laid on the analysis of the vectors' epi-
somal replication potential, but not on transgene expres-
sion levels [3,7-9]. In these studies partial, i.e.
background, integration of few pEPI-vectors was never
fully excluded, but the episomal maintenance and replica-
tion was described [1-4,6-9]. When assaying all novel
EGFP-IRES-BSD cassette containing vectors, the CpG-
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Page 9 of 14depleted, pEPito based constructs constantly performed
better than the pEPI-1 based constructs, with respect to
transient transfection efficiencies, transient EGFP
expression levels, EGFP expression levels within stably
selected cells, and colony-forming efficiency (Figure 3, 4).
Since all experiments were performed by transfecting
equal amounts of vector DNA - and not equal molar
ratios of vector molecules,- to exclude side effects of
stuffer DNA, some of the differences within the increased
transient transfection efficiencies of the smaller plasmids
are caused by this. pEPito-based vectors are on average
some 25% smaller than their respective pEPI-1-based
counterparts and as a consequence ~one third more
pEPito vector molecules as compared to its direct pEPI-1
counterpart had been transfected initially. The differ-
ences in transient EGFP expression, the EGFP expression
levels of stably selected mixed-clones, and the 7-70 fold
increase in colony-forming efficiency are impressive and
not caused by the different equimolar levels of the trans-
fected DNA, which differ at a maximum of 33%. The
Figure 5 Increased and prolonged expression of pEPito in vivo. Luciferase expression profiles of exemplary MF-1 mice hydrodynamically injected 
with the vectors #9-13 (Figure 2 as assayed by in vivo bioluminescence imaging after 1 (first column), 7 (second column), 14 (third column), and 32 
(fourth column) days post injection. The vector pEPI-1- [CMV-IEP]- [Luc] has been previously published as pEPI-Luc [32].
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about 1-5% [8]. In our modified experimental setup this
efficiency was lower, considering the colony-forming
assay, the initial transfection rate and cell growth, and
resulted in about 0,25% of the transfected and selected
cells for the pEPI-1- [CMV]-construct, and - ~6 fold
higher - about 1,8% for the comparable pEPito- [CMV]-
construct in HEK 293.
Increased transgene expression levels and longer last-
ing transgene expression in vitro and in vivo have also
been reported for so-called minicircles which lack any
residual elements necessary for bacterial propagation
[33,34], or for CpG-depleted or CpG-free vectors that have
been constructed depleted or free of any CpG motives
[35,36]. It was shown, that the CpG content of a minicir-
cles' transgene transcription unit does not affect the epi-
genetic silencing of its transgene [37], in contrast to
epigenetic elements present in the bacterial origin of rep-
lication or backbone [38]. Chen et al. speculate that there
might be a recruitment of repressive heterochromatin as
inducer of a silencing complex that is initiated within
bacterial vector elements [20], implying an important
role of the chromatin structure for epigenetic silencing.
As bacterial elements usually contain CpG motifs, the
known effects of CpG-isles and the work of Chen et al.
[20] are neither identical nor contradictory, but these
effects might be linked at some points in our understand-
ing. Further research has to elucidate, if and how these
facts are connected. No or only weak silencing effects
have been described within CpG-free plasmids
[17,21,35]. Our novel pEPito vector, which consists of a
rather CpG-rich transgene transcription unit within a
CpG-depleted bacterial vector backbone, seems to
exhibit similar expression profiles as the described
minicircles and CpG-free vectors.
The CMV-IEP promoter element is frequently used
within commercial plasmid vectors, since it confers
robust expression of a transgene in several cell types. The
expression profile of CMV-IEP, however, decreases
steadily over time, which could be explained by methyla-
tion of cytosines within this promoter region [19]. For
pEPI-1 based vectors methylation of cytosines within the
CMV-IEP promoter region has been reported to be
inhibited by the vector encoded MARS element in CHO
and HaCat cells in vitro [39]. In contrast, Argyros et al.
described silencing of a CMV-IEP promoter driven
luciferase transgene within a pEPI-1 vector backbone
after hydrodynamic gene delivery in mice. Within the lat-
ter study, however, the cytosine methylation of the CMV-
IEP promoter element has not been investigated in detail
[32]. Taken together, no cytosine methylation of CMV-
IEP promoter elements within pEPI-based vectors has
been observed so far in vitro and in vivo. Therefore, a
possible explanation for the silencing of transgenes regu-
lated by the CMV-IEP promoter element within a pEPI-
vector backbone might be histone deacetylation as pro-
posed by Papapetrou et al. [40].
When comparing the CMV-IEP and hCMV/EF1P pro-
moter elements within our constructs (Figure 3, 4), it is
obvious that the relative promoter strength has a strong
influence on vector performance. In case of stably
selected HEK293 cells, CMV-IEP promoter based vectors
exhibited a stronger transgene expression - as a measure
of promoter strength - as vectors based on the relatively
weaker hCMV/EF1P promoter element (Figure 4A). This
situation, however, is inverted in stably selected NIH3T3
mixed-clones, in which the hCMV/EF1P promoter ele-
ment results in higher transgene expression levels than
the CMV-IEP (Figure 4B). We assume that increased
transgene expression levels reflect increased transgene
mRNA transcription levels, despite this has not been
experimentally verified so far.
In both, HEK293 and NIH3T3 cells, the colony-form-
ing efficiency of vectors with a functional pEPI-plasmid
replicon, i.e. all MARS containing vectors, seems to par-
tially correlate with the relative promoter strength (Figure
4). The rather weak performance of the CMV-IEP pro-
moter element within NIH3T3 cells has been already
described by Nehlsen et al. [41]. These findings suggest,
that the CMV-IEP promoter element seems to be
extraordinarily susceptible for epigenetic silencing within
NIH3T3 cells. For the latter cell line rapid silencing of
exogenous plasmid DNA by histone deacetylation has
been frequently observed [42,43]. The hypothesis pre-
sented in Chen et al. [20], i.e. the formation of hetero-
chromatin after histone deacetylation involvement [44-
47] triggered by certain bacterial elements, may serve as
an explanation for the better performance of pEPito
based vectors with respect to transgene expression and
colony-forming efficiency within stably selected NIH3T3
cells (Figure 4B, D), since the pEPI-1 vector backbones
exhibit significantly higher numbers of CpG motives (Fig-
ure 2).
The positive effect of the MARS element within the dif-
ferent pEPI-vector backbones can be observed best
within our colony-forming assays in vitro and within the
expression profiles of our MF-1 mice in vivo. In all col-
ony-forming assays the presence of a MARS as a func-
tional component of the pEPI-vector plasmid replicon
(Figure 1) increased the number of established colonies as
compared to their respective control vectors without
MARS (Figure 4C, D). This could be explained by the epi-
somal replication of respective vectors, which could be
further supported by bacterial rescue experiments (Table
1). The CpG depleted backbone also influences the col-
ony forming efficiencies. As the pEPI-replicon needs the
transcription into the MARS-Element to establish an epi-
some, the higher transgene expression of the pEPito vec-
Haase et al. BMC Biotechnology 2010, 10:20
http://www.biomedcentral.com/1472-6750/10/20
Page 11 of 14tors might lead to a higher chance of an establishing
event, resulting in higher colony forming unit numbers.
In MF-1 mice the pEPito based vectors with the MARS
elements resulted in prolonged transgene expression
(Figure 5). Since liver cells are quiescent cells, episomal
replication of pEPI-based vectors might not serve as a
suitable explanation for the prolonged transgene expres-
sion. Above all, we showed by qPCR that all five hydrody-
namically delivered vectors persisted at equal copy
numbers of approximately 0.5 - 6 vector molecules per
liver cell. The failure of rescuing of the pEPI-1 based vec-
tor could be due to the formation of heterochromatin as
discussed for the in vitro results before. We favour the
theory, that the prolonged transgene expression profiles
of pEPito-based vectors in vivo results from a combina-
tion of (1) reduced epigenetic silencing due to the modi-
fied bacterial vector backbone [17,20,23,35,48], and (2)
the presence of the MARS which might trigger the trans-
location of vector molecules to sites of active chromatin
(Figure 1) [8], or enhance overall transcription levels
[49,50].
Conclusions
In conclusion, we developed a CpG-depleted pEPI-vector
derivative named pEPito in this study which combines
the ability of episomal replication and mitotic stability
described for pEPI-based vectors with the diminished
tendency towards epigenetic silencing of vector encoded
transgenes due to the CpG depletion of the vector back-
bone. In contrast to recently described minicircles,
pEPito-based vectors can be propagated, modified, and
amplified in E.coli DB3.1λpir. We could further demon-
strate, that the CpG content and/or the bacterial vector
backbone of any plasmid vector exhibits a strong influ-
ence on long-term transgene expression. The detailed
molecular mechanism of the epigenetic silencing of vec-
tor encoded transgenes has to be further investigated.
Our novel pEPito vector will have crucial implementa-
tions for biotechnological applications in vitro, e.g. within
the fast generation of stably selected mixed-clone cells
with arbitrary transgenes at low costs. Due to its ability
for prolonged transgene expression in vivo, pEPito is also
expected to serve as an improved vector for non-viral
gene therapy.
Methods
Vector construction
The construction of the pEPI-1 and pEPI-1ΔMARS vec-
tor backbones have been described previously [1]. The
individual functional elements of the vector can be
exchanged by restriction digest and ligation using PciI/
NheI (promoter element), NheI/BglII (transgene tran-
scription unit), or BglII/MluI (MARS). For the construc-
tion of the pEPito and pEPito-ΔMARS vector backbones,
a 729 bp long DNA fragment, containing a CpG free
R6Kori and a zeocin resistance cassette, of the vector
pCpG-MCS (Invivogen, France) was isolated by PacI
restriction and gel purification. This R6Kori PacI frag-
ment was ligated to the 918 bp long CpG depleted β-lac-
tamase gene (BLA) cassette of the vector pMOD-LucSH
(Invivogen, France). The latter (BLA) cassette was PCR-
amplified from pMOD-LucSH in a way that PacI restric-
tion sites were added to either ends by primer mutagene-
sis. For further subcloning purposes, an additional XhoI
site was added to the 5' end of the BLA cassette. The
resulting first shuttle vector (pHulk-ΔMCS) consisted of
a CpG free R6Kori, a CpG depleted BLA cassette, and a
XhoI single cutter site. A multiple cloning site consisting
of the restriction enzyme sites XhoI, PciI, NheI, BglII,
MluI, and XhoI was generated by primer annealing and
inserted into the single XhoI site of pHulk-ΔMCS. The
resulting shuttle vector (pHulk) served as a template for
the construction of all pEPito and pEPito-ΔMARS vec-
tors.
As described above for the pEPI-1 and pEPI-1-ΔMARS
vector backbones, the individual functional vector ele-
ments could be inserted into pHulk by restriction digest
and ligation using PciI/NheI (promoter elements), NheI/
BglII (transgene transcription units), or BglII/MluI
(MARS). The Cytomegalovirus immediate early promoter
(CMV-IEP) element was isolated as PciI and NheI frag-
ment out of pEGFP-C1 (Clontech, USA). The human
CMV enhancer/human elongation factor 1 alpha pro-
moter (hCMV/EF1P) element was PCR-amplified out of
pCPG-hCMV-Luc using 5' NheI and 3' BglII primers. For
the construction of the EGFP-BSD cassette connected via
internal ribosomal entry site (EGFP-IRES-BSD), the BSD
cassette of pLenti6.2/V5-DEST (Invitrogen, USA) has
been PCR-amplified by using a 5' primer that contains a
BglII site and a recently described, 22 bp long synthetic
IRES module [25] and a 3' primer containing a BamHI
site. The resulting PCR-fragment containing IRES-BSD
was inserted via BglII and BamHI into the single BglII site
of pEGFP-C1 (Clontech, USA) or pEPI-1 [1]. After check-
ing the correct orientation, the IRES-BSD transgene tran-
scription unit could be isolated with or without MARS
element from the respective vectors (Figure 1E, #2 and
#1) as BglII and MluI fragments. The EGFP-luciferase
fusion protein (EGFP::Luc) [27,28] was PCR-amplified
from pEGFPLuc (Clontech, USA) using 5' NheI and 3'
BglII primers. The vector pEPI-1- [CMV-IEP]- [Luc] (Fig-
ure 1E, #9) has been described earlier [32]. All 13 differ-
ent vectors used within this work were constructed,
propagated, and amplified in E.coli DB3.1λpir [30]. The
integrity of vectors was verified by sequencing (AGOWA,
Germany). Additional information about vector sizes and
total amounts of CpG motives are provided in the last
two columns of Figure 2E. Vector DNA was prepared
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according to the manufacturer's instructions and stored
at 4°C until usage. Freezing of the purified vector DNA
was avoided to prevent shearing of the DNA.
Mammalian cell culture and transfection
HEK293 and NIH3T3 cells were cultured in Dulbecco's
modified Eagle medium supplemented with 10% FCS and
1% glutamine (Gibco, USA). For transfection experi-
ments, 2 × 105 cells were seeded into a 6 well plate (BD
Falcon, USA) 24 hours prior to the experiment. Transfec-
tions were performed using 0,5 μg vector DNA and
Fugene6 (Roche, Germany) as transfection reagent
according to the manufacturer's instructions.
Flow cytometry
Two days (48 hours) post transfection the cells were
trypsinized, resuspended in phosphate buffered saline
(PBS) (Invitrogen, Germany), and divided into two
halves. One half was used for immediate flow cytometric
analysis of EGFP expression using a FACS Canto II device
(Becton Dickinson, Germany). The other half was cul-
tured in the presence of either blasticidin (7 ng/ml) or
geneticin (400 ng/ml) (PAA, Austria). After 28 days of
selection, stably selected (mixed-clone) cells were again
analyzed for EGFP expression. EGFP signal was mea-
sured in duplicates at 488 and 567 nm to exclude autoflu-
orescence of different cell lines.
Colony-forming assay
For colony forming assays, transfected cells were split
from 6 well plates into 75 cm2 flasks at 48 hours post
transfection. Splitting of cells was performed at serial
dilutions (1:1, 1:10, and 1:100). After a total of 30 days of
selection, with either blasticidin or geneticin, formed col-
onies were fixed with 4% paraformaldehyde (Sigma, Ger-
many) in PBS, counterstained with methylene blue
(Sigma, Germany) and counted.
Isolation of genomic DNA from cell lines and mouse liver
For isolation of genomic DNA from transfected and sta-
bly selected cell lines, cells were trypsinized, resuspended
in PBS, and counted. Genomic DNA was isolated from
107 cells using the QiaAMP DNA Mini Kit (Qiagen, Ger-
many) according to the manufacturer's instructions. For
isolation of genomic DNA from shock frozen mouse liver,
small pieces of about 25 mg were cut on dry ice. Genomic
DNA was isolated immediately using the QiaAMP DNA
Mini Kit (Qiagen, Germany) according to the manufac-
turer's instructions.
Bacterial rescue experiments
Bacterial rescue experiments to verify the episomal status
of pEPI-based vectors within transfected and stably
selected mammalian cell lines or liver tissues were per-
formed by chemical transformation of 10 μl of isolated
genomic DNA (approximately 500 ng) in chemical com-
petent E.coli GT115 (Invivogen, France). Transformed
bacteria were selected on LB-plates containing either
ampicillin, or kanamycin depending on respective bacte-
rial selection markers (Table 1). Plasmid DNA was pre-
pared out of transformed bacteria using the Qiaprep Spin
Miniprep Kit (Qiagen, Germany) according to the manu-
facturer's instructions. The integrity of the rescued plas-
mids was checked by restriction analysis and gel
electrophoresis. For rescue experiments of cell culture
materials, chromosomal DNA of stably selected mixed
clones was isolated three times independently and trans-
formed into bacteria. Resulting bacterial clones were
analysed for the integrity of their isolated plasmids. In
case no colonies could be obtained from the initial trans-
formations, this procedure was repeated for two more
times. For rescue experiments of liver tissue materials,
the DNA of three different livers was isolated three times
independently and transformed into bacteria as
described above.
Hydrodynamic plasmid injection of animals and in vivo 
bioluminescence imaging
MF-1 mice (1-2 months old, 20-25 g, male) (B&K Univer-
sal Ltd., UK) were rapidly injected, over 5-8 seconds, via
the tail vein with 2.5 ml PBS containing 30 μg of each
plasmid vector DNA using a 27-gauge needle. Animals
were given appropriate care in compliance with institu-
tional and UK guidelines. All animal procedures were
conducted in accordance with the Animal (Scientific Pro-
cedures) Act 1986, and after appropriate local ethical
review. At 1, 7, 14, 21, and 32 days after hydrodynamic
injection, mice were dosed intraperitoneally (i.p.) with
300 μl of D-luciferin (Gold Biotechnology, USA) (15 mg/
ml in PBS), anesthetized by isoflurane, and then imaged
for bioluminescence by the IVIS Imaging 50 Series
(Xenogen, USA). Bioluminescence imaging (BLI) was
performed in a light-tight chamber on a temperature-
controlled, adjustable stage while isoflurane was adminis-
tered by means of a gas manifold at a flow rate of 2%.
Images were acquired at a medium binning level (8) and a
20-cm Weld of view. Acquisition times were either 5 or 10
sec, depending on the intensity of the luminescence. The
Xenogen system reported bioluminescence as photons/
sec/cm2/sr (seradian) in a 2.86-cm-diameter region of
interest covering the liver. The auto function was used to
define the minimum for the scale at each time point. This
value was 5% of the maximum in each case. Data were
analysed by using LIVINGIMAGE 2.50 software (Xeno-
gen, USA). Background levels of bioluminescence were 1
× 106 photons/sec/cm2/sr. Comparison of luciferase
expression resulting from the various constructs was
analysed by one-way ANOVA to assess statistical signifi-
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(Tukey's HSD) was further performed to assess pairwise
differences on expression confirmed by ANOVA with a
significance level p = 0.05.
Quantitative PCR
The quantitative PCR (qPCR) for the detection of vector
molecules within genomic DNA isolated from mouse
liver was performed on an AB Prism 7500 SDS device
using FastStart Universal Probe Master (Roche, USA).
Vector molecules were detected using probe (5'Fam-
CGCCCAACACCGGCA TAAAGA-3'Tamra) and prim-
ers (TTGGCAGAAGCTATGAAACG, GCAAC
TGCAACTCCGATAAA) against the luciferase gene (Ella
Biotech, Germany). For standardization, probe (5'Joe-
CAAACACGAACCATCCGCCG-3'Tamra) and primers
(CAGCATCAATGGCAACTTCT, GAAGATTGATC-
CGTGGCTTT) against the neurogenic differentiation 1
(ND1) gene were used. A standard curve with a luciferase
containing plasmid was generated, and vector copy num-
bers per liver cell were calculated from the differences in
cycle numbers of the internal standard (ND1) compared
to the target (luciferase).
List of abbreviations
BLA: β-lactamase; bp: basepair; BSD: blasticidine S
deaminase; CMV: Cytomegalovirus; CpG: Cytosine-
phosphatidyl-Guanosine; d.p.i.: days post injection; d.p.t.:
days post transfection; EBV: Epstein-Barr virus; EF1P:
elongation factor 1 promoter; EGFP: enhanced green flu-
orescent protein; EGFP::Luc: EGFP-luciferase fusion pro-
tein; G418: geneticin; hCMV: human cytomegalovirus;
IEP: immediate early promoter; IRES: internal ribosomal
entry site; kb: kilobasepair; Luc: luciferase; MARS: matrix
attachment region sequence; MCS: multiple cloning site;
NPT: neomycin phosphotransferase; ORC: origin recog-
nition complex; Ori: origin of replication; PBS: phosphate
buffered saline; qPCR: quantitative PCR; SAF-A: scaffold
attachment factor A; shRNA: small hairpin RNA; SD:
standard deviation; SV40-O/P: Simian virus 40 Ori/pro-
moter; TLR: Toll-like receptor
Additional material
Authors' contributions
RH constructed all vectors described in this manuscript and performed the
majority of in vitro experiments. OA performed all animal (in vivo) experiments.
SPW contributed in the in vivo bioluminescence imaging. RPH provided super-
vision of all animal (in vivo) experiments. HJL and MO contributed in vector
design and construction. TM contributed in real time PCR design and perfor-
mance. MVP contributed in genomic DNA isolation of cell lines and mouse
liver. JH and AB provided supervision. RH and AB drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
Financial support by the Deutsche Forschungsgemeinschaft (BA 2035/3-1 and 
SPP1230 priority program "Mechanisms of gene vector entry and persistence") 
and the Bundesministerium fuer Bildung und Forschung (BMBF BioChance-
PLUS/FKZ: 0315182) to AB is gratefully acknowledged. We kindly acknowledge 
Michael Kahn for providing E.coli DB3.1λpir. Furthermore we like to thank Helga 
Mairhofer and Georg Malterer for their help with real time PCR and Anja 
Ehrhardt for her help with Southern blotting.
Author Details
1Max von Pettenkofer-Institute, University of Munich, Munich, Germany, 
2National Heart and Lung Institute, Imperial College London, London, UK, 
3Institute for Cell Biology, University of Witten/Herdecke, Witten, Germany, 
4Department of Pharmacy, University of Munich, Munich, Germany and 
5Division of Pathway Medicine, University of Edinburgh, Edinburgh, UK
References
1. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ: A vector based on the 
SV40 origin of replication and chromosomal S/MARs replicates 
episomally in CHO cells.  Nucleic Acids Res 1999, 27:426-428.
2. Bode J, Kohwi Y, Dickinson L, Joh T, Klehr D, Mielke C, Kohwi-Shigematsu 
T: Biological significance of unwinding capability of nuclear matrix-
associating DNAs.  Science 1992, 255:195-197.
3. Baiker A, Maercker C, Piechaczek C, Schmidt SB, Bode J, Benham C, Lipps 
HJ: Mitotic stability of an episomal vector containing a human scaffold/
matrix-attached region is provided by association with nuclear matrix.  
Nat Cell Biol 2000, 2:182-184.
4. Jenke AC, Stehle IM, Herrmann F, Eisenberger T, Baiker A, Bode J, 
Fackelmayer FO, Lipps HJ: Nuclear scaffold/matrix attached region 
modules linked to a transcription unit are sufficient for replication and 
maintenance of a mammalian episome.  Proc Natl Acad Sci USA 2004, 
101:11322-11327.
5. Jenke AC, Eisenberger T, Baiker A, Stehle IM, Wirth S, Lipps HJ: The 
nonviral episomal replicating vector pEPI-1 allows long-term inhibition 
of bcr-abl expression by shRNA.  Hum Gene Ther 2005, 16:533-539.
6. Schaarschmidt D, Baltin J, Stehle IM, Lipps HJ, Knippers R: An episomal 
mammalian replicon: sequence-independent binding of the origin 
recognition complex.  EMBO J 2004, 23:191-201.
7. Jenke BH, Fetzer CP, Stehle IM, Jonsson F, Fackelmayer FO, Conradt H, 
Bode J, Lipps HJ: An episomally replicating vector binds to the nuclear 
matrix protein SAF-A in vivo.  EMBO Rep 2002, 3:349-354.
8. Stehle IM, Postberg J, Rupprecht S, Cremer T, Jackson DA, Lipps HJ: 
Establishment and mitotic stability of an extra-chromosomal 
mammalian replicon.  BMC Cell Biol 2007, 8:33.
9. Stehle IM, Scinteie MF, Baiker A, Jenke AC, Lipps HJ: Exploiting a minimal 
system to study the epigenetic control of DNA replication: the 
interplay between transcription and replication.  Chromosome Res 2003, 
11:413-421.
Additional file 1 Representative FACS-diagrams corresponding to fig-
ure 3A. This additional file depicts representative flow cytometry profiles 
corresponding to all bars shown in figure 3A (transiently transfected 
HEK293 cells).
Additional file 2 Representative FACS-diagrams corresponding to fig-
ure 4A.Description: This additional file depicts representative flow cytome-
try profiles corresponding to all bars shown in figure 4A (stably selected 
mixed-clone HEK293 cells).
Additional file 3 Quantification of expression profiles in vivo. This 
additional file depicts graphically the extended longitudinal expression 
study of the mice for up to 32 days. Luciferase expression is quantified using 
Xenogen Living Image software and represented as photons/sec/cm2/sr. 
Background level of light emission on non-treated animals is 1 × 106 pho-
tons/sec/cm2/sr. Standard error of the mean for each time point is indi-
cated.
Received: 20 November 2009 Accepted: 15 March 2010 
Published: 15 March 2010
This article is available from: http://www.biomedcentral.com/1472-6750/10/20© 2010 Haa e et al; licensee BioMed Central Ltd. is an Op n Access article distribut d under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2010, 10:20
Haase et al. BMC Biotechnology 2010, 10:20
http://www.biomedcentral.com/1472-6750/10/20
Page 14 of 1410. Ren C, Zhao M, Yang X, Li D, Jiang X, Wang L, Shan W, Yang H, Zhou L, 
Zhou W, et al.: Establishment and applications of epstein-barr virus-
based episomal vectors in human embryonic stem cells.  Stem Cells 
2006, 24:1338-1347.
11. Eisenberger T, Lipps HJ, Mueller M, Baiker A: A human papillomavirus 
(HPV)-based pseudoviral gene delivery system for the non-viral, 
episomally replicating vector pEPI-1.  Gene Ther Mol Biol 2005, 9:371-376.
12. Leight ER, Sugden B: Establishment of an oriP replicon is dependent 
upon an infrequent, epigenetic event.  Mol Cell Biol 2001, 21:4149-4161.
13. Bestor TH: The DNA methyltransferases of mammals.  Hum Mol Genet 
2000, 9:2395-2402.
14. Bird AP: CpG-rich islands and the function of DNA methylation.  Nature 
1986, 321:209-213.
15. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking 
innate and acquired immunity.  Nat Immunol 2001, 2:675-680.
16. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner 
H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via 
species-specific CpG motif recognition.  Proc Natl Acad Sci USA 2001, 
98:9237-9242.
17. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, 
Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, et al.: CpG-free 
plasmids confer reduced inflammation and sustained pulmonary gene 
expression.  Nat Biotechnol 2008, 26:549-551.
18. Boyes J, Bird A: Repression of genes by DNA methylation depends on 
CpG density and promoter strength: evidence for involvement of a 
methyl-CpG binding protein.  EMBO J 1992, 11:327-333.
19. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM: 
Transcriptional silencing is associated with extensive methylation of 
the CMV promoter following adenoviral gene delivery to muscle.  J 
Gene Med 2004, 6:395-404.
20. Chen ZY, Riu E, He CY, Xu H, Kay MA: Silencing of episomal transgene 
expression in liver by plasmid bacterial backbone DNA is independent 
of CpG methylation.  Mol Ther 2008, 16:548-556.
21. Pringle IA, Raman S, Sharp WW, Cheng SH, Hyde SC, Gill DR: Detection of 
plasmid DNA vectors following gene transfer to the murine airways.  
Gene Ther 2005, 12:1206-1214.
22. Akira S, Hemmi H: Recognition of pathogen-associated molecular 
patterns by TLR family.  Immunol Lett 2003, 85:85-95.
23. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng 
SH: CpG-depleted plasmid DNA vectors with enhanced safety and 
long-term gene expression in vivo.  Mol Ther 2002, 5:731-738.
24. Wu F, Levchenko I, Filutowicz M: A DNA segment conferring stable 
maintenance on R6K gamma-origin core replicons.  J Bacteriol 1995, 
177:6338-6345.
25. Chappell SA, Mauro VP: The internal ribosome entry site (IRES) 
contained within the RNA-binding motif protein 3 (Rbm3) mRNA is 
composed of functionally distinct elements.  J Biol Chem 2003, 
278:33793-33800.
26. Gould SJ, Subramani S: Firefly luciferase as a tool in molecular and cell 
biology.  Anal Biochem 1988, 175:5-13.
27. de Wet  Jr, Wood KV, DeLuca M, Helinski DR, Subramani S: Firefly 
luciferase gene: structure and expression in mammalian cells.  Mol Cell 
Biol 1987, 7:725-737.
28. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC: Green fluorescent 
protein as a marker for gene expression.  Science 1994, 263:802-805.
29. Prasher DC, Eckenrode VK, Ward WW, Prendergast FG, Cormier MJ: 
Primary structure of the Aequorea victoria green-fluorescent protein.  
Gene 1992, 111:229-233.
30. House BL, Mortimer MW, Kahn ML: New recombination methods for 
Sinorhizobium meliloti genetics.  Appl Environ Microbiol 2004, 
70:2806-2815.
31. Ochiai H, Harashima H, Kamiya H: Silencing of exogenous DNA in 
cultured cells.  Biol Pharm Bull 2006, 29:1294-1296.
32. Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller 
AD, Harbottle RP: Persistent episomal transgene expression in liver 
following delivery of a scaffold/matrix attachment region containing 
non-viral vector.  Gene Ther 2008, 15:1593-1605.
33. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J: A new DNA 
vehicle for nonviral gene delivery: supercoiled minicircle.  Gene Ther 
1997, 4:1341-1349.
34. Chen ZY, He CY, Ehrhardt A, Kay MA: Minicircle DNA vectors devoid of 
bacterial DNA result in persistent and high-level transgene expression 
in vivo.  Mol Ther 2003, 8:495-500.
35. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK: Long-term 
transgene expression from plasmid DNA gene therapy vectors is 
negatively affected by CpG dinucleotides.  Mol Ther 2004, 10:269-278.
36. de Wolf HK, Johansson N, Thong AT, Snel CJ, Mastrobattista E, Hennink 
WE, Storm G: Plasmid CpG depletion improves degree and duration of 
tumor gene expression after intravenous administration of polyplexes.  
Pharm Res 2008, 25:1654-1662.
37. Chen ZY, He CY, Kay MA: Improved production and purification of 
minicircle DNA vector free of plasmid bacterial sequences and capable 
of persistent transgene expression in vivo.  Hum Gene Ther 2005, 
16:126-131.
38. Chen ZY, He CY, Meuse L, Kay MA: Silencing of episomal transgene 
expression by plasmid bacterial DNA elements in vivo.  Gene Ther 2004, 
11:856-864.
39. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ: Expression of a transgene 
encoded on a non-viral episomal vector is not subject to epigenetic 
silencing by cytosine methylation.  Mol Biol Rep 2004, 31:85-90.
40. Papapetrou EP, Ziros PG, Micheva ID, Zoumbos NC, Athanassiadou A: 
Gene transfer into human hematopoietic progenitor cells with an 
episomal vector carrying an S/MAR element.  Gene Ther 2006, 13:40-51.
41. Nehlsen K, Broll S, Bode J: Replicating minicircles: Generation of nonviral 
episomes fort the efficient modification of dividing cells.  Gene Ther Mol 
Biol 2006, 10:233-244.
42. Kim JM, Liu H, Tazaki M, Nagata M, Aoki F: Changes in histone acetylation 
during mouse oocyte meiosis.  J Cell Biol 2003, 162:37-46.
43. Nagashima T, Maruyama T, Furuya M, Kajitani T, Uchida H, Masuda H, Ono 
M, Arase T, Ozato K, Yoshimura Y: Histone acetylation and subcellular 
localization of chromosomal protein BRD4 during mouse oocyte 
meiosis and mitosis.  Mol Hum Reprod 2007, 13:141-148.
44. Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional 
silencing and longevity protein Sir2 is an NAD-dependent histone 
deacetylase.  Nature 2000, 403:795-800.
45. Kimura A, Umehara T, Horikoshi M: Chromosomal gradient of histone 
acetylation established by Sas2p and Sir2p functions as a shield 
against gene silencing.  Nat Genet 2002, 32:370-377.
46. Suka N, Luo K, Grunstein M: Sir2p and Sas2p opposingly regulate 
acetylation of yeast histone H4 lysine16 and spreading of 
heterochromatin.  Nat Genet 2002, 32:378-383.
47. Zhang J, Xu F, Hashimshony T, Keshet I, Cedar H: Establishment of 
transcriptional competence in early and late S phase.  Nature 2002, 
420:198-202.
48. Yew NS, Cheng SH: Reducing the immunostimulatory activity of CpG-
containing plasmid DNA vectors for non-viral gene therapy.  Expert 
Opin Drug Deliv 2004, 1:115-125.
49. Bode J, Benham C, Knopp A, Mielke C: Transcriptional augmentation: 
modulation of gene expression by scaffold/matrix-attached regions (S/
MAR elements).  Crit Rev Eukaryot Gene Expr 2000, 10:73-90.
50. Dang Q, Auten J, Plavec I: Human beta interferon scaffold attachment 
region inhibits de novo methylation and confers long-term, copy 
number-dependent expression to a retroviral vector.  J Virol 2000, 
74:2671-2678.
doi: 10.1186/1472-6750-10-20
Cite this article as: Haase et al., pEPito: a significantly improved non-viral 
episomal expression vector for mammalian cells BMC Biotechnology 2010, 
10:20
